The Role of Irisin, Copper and Zinc Levels on Insulin Resistance in Polycystic Ovary Syndrome

Yıl 2020, Cilt: 1 Sayı: 1, 12 - 18, 22.09.2020

Mustafa Bayraktar Ali Sami Gürbüz Bahadır Öztürk

https://doi.org/10.47482/acmr.2020.2

Cited By: 1

Öz

Background: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Irisin is defined as a myocin released from skeletal muscle that protects individuals from metabolic diseases when exercised regularly. Zinc is thought to play an active role in the pathophysiology of PCOS in relation to insulin resistance. Copper has been stated to contribute to oxidative stress and insulin resistance in PCOS patients. The aim of this study was to evaluate the relationship between serum irisin, copper and zinc levels and insulin resistance in PCOS patients and control cases.

Methods: Our study consists of a patient group of 45 individuals diagnosed with PCOS and a healthy control group of 45 individuals. 2003 Rotterdam diagnostic criteria were used for the diagnosis of PCOS. Serum copper, zinc and irisin levels were measured and evaluated with regard to Body Mass Index and insulin resistance.

Results: Serum zinc and copper levels were found to be higher in PCOS patients compared to controls (p<0.05), however no statistically significant differences were found between the groups with regard to HOMA-IR and serum irisin levels. Conclusions: It was evaluated that the data obtained from the patient group in this study may have been effected due to patients’ use of some medications like metformin, multivitamin supplements and oral contraceptives.

Anahtar Kelimeler

PCOS, Irisin, Insulin Resistance, Copper, Zinc

Kaynakça

• 1.Di Pietro M, Pascuali N, Parborell F, Abramovich D. Ovarian angiogenesis in polycystic ovary syndrome. Reproduction. 2018;155(5):R199-R209.
• 2. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia, USA: lippincott Williams & wilkins; 2005.
• 3. Shannon M, Wang Y. Polycystic ovary syndrome: a common but often unrecognized condition. Journal of midwifery & women’s health. 2012;57(3):221-30.
• 4. Baysal B. Polikistik over sendromu ve hirsutizm. İÜ Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Sempozyum Dizisi2008. p. 99-107.
• 5. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews. 2016;37(5):467-520.
• 6. Evliyaoglu O. Polycystic ovary syndrome and hirsutism/Polikistik over sendromu ve hirsutizm. J Turkish Pediatrics Archive. 2011:S97-S.
• 7. Vrbíková J, Bendlová B, Hill M, Vanková M, Vondra K, Stárka L. Insulin sensitivity and β-cell function in women with polycystic ovary syndrome. J Diabetes Care. 2002;25(7):1217-22.
• 8. Kucur SK, Yüksel B, Seven A, Polat M, Keskin N, Aksoy AN. Farklı Dört Polikistik Over Sendromu Fenotipinin Klinik Ve Laboratuvar Değerlerinin Karşılaştırılması. J Mustafa Kemal Üniversitesi Tıp Dergisi. 2016;7(26).
• 9. Şahin SB, Sümer F, Sezgin H, Ayaz T, Şahin OZ, İlkkılıç K, et al. Polikistik over sendromlu hastalarda obezitenin klinik, metabolik ve hormonal özellikler üzerine etkisi. J Journal of Clinical Experimental Investigations. 2014;5(4):567-71.
• 10. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. J International journal of obesity. 2007;31(2):S8-S13.
• 11. Aslan NN, Yardımcı H. Obezite üzerine etkili yeni bir hormon: İrisin. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. 2017;6(3):176-83.
• 12. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Position statement: glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. The Journal of Clinical Endocrinology Metabolism. 2007;92(12):4546-56.
• 13. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8.
• 14. Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides. 2014;56:94-110.
• 15. Masaeli A, Nayeri H, Mirzaee M. Effect of metformin treatment on insulin resistance markers, and circulating irisin in women with polycystic ovarian syndrome (PCOS). Hormone Metabolic Research. 2019;51(09):575-9.
• 16. Abali R, Temel Yuksel I, Yuksel MA, Bulut B, Imamoglu M, Emirdar V, et al. Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome. Journal of Obstetrics Gynaecology. 2016;36(7):897-901.
• 17. Zhang L, Fang X, Li L, Liu R, Zhang C, Liu H, et al. The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. Journal of endocrinological investigation. 2018;41(12):1401-7.
• 18. Wang C, Zhang X-Y, Sun Y, Hou X-G, Chen LJGE. Higher circulating irisin levels in patients with polycystic ovary syndrome: a metaanalysis. Gynecological Endocrinology. 2018;34(4):290-3.
• 19. Pukajło K, Łaczmański Ł, Kolackov K, Kuliczkowska-Płaksej J, Bolanowski M, Milewicz A, et al. Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecological Endocrinology. 2015;31(11):907-11.
• 20. Gao S, Cheng Y, Zhao L, Chen Y, Liu Y. The relationships of irisin with bone mineral density and body composition in PCOS patients. Diabetes/metabolism research reviews. 2016;32(4):421-8.
• 21. Qiu S, Cai X, Yin H, Zügel M, Sun Z, Steinacker JM, et al. Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metabolism. 2016;65(6):825-34.
• 22. Cai L, Li X, Song Y, Cherian M. Essentiality and Toxicology of Zinc and Copper and its chelation therapy. Current Medicinal Chemistry. 2005;12.23:2753-63.
• 23. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiological reviews. 1993;73(1):79-118.
• 24. Coleman JEJArob. Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins. Annual review of biochemistry. 1992;61:897-946.
• 25. Maktabi M, Jamilian, M., & Asemi, Z. . Magnesium-zinc-calciumvitamin D co-supplementation improves hormonal profiles, biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebocontrolled trial. Biological trace element research, . 2018;182(1):21-8.
• 26. Belviranli M, Okudan N, Karakuyu N. The association between irisin levels, element distribution and oxidative stress markers in adolescent swimmers. Hormone molecular biology clinical investigation. 2018;34(3).
• 27. Hess SY, Lönnerdal B, Hotz C, Rivera JA, Brown KH. Recent advances in knowledge of zinc nutrition and human health. Food nutrition bulletin. 2009;30(1_suppl1):S5-S11.
• 28. Kim J, Lee S. Effect of zinc supplementation on insulin resistance and metabolic risk factors in obese Korean women. Nutrition research practice. 2012;6(3):221-5.
• 29. Abedini M, Ghaedi E, Hadi A, Mohammadi H, Amani R. Zinc status and polycystic ovarian syndrome: A systematic review and metaanalysis. Journal of Trace Elements in Medicine Biology. 2019;52:216-21.
• 30. Kanafchian M, Mahjoub S, Esmaeilzadeh S, Rahsepar M, Mosapour A. Status of serum selenium and zinc in patients with the polycystic ovary syndrome with and without insulin resistance. Middle East Fertility Society Journal. 2018;23(3):241-5.
• 31. Kulhan M, Kulhan NG, Nayki UA, Nayki C, Ata N, Ulug P, et al. Assessment of the relationship between serum vitamin (A, B 12, C, D, folate) and zinc levels and polycystic ovary syndrome. Archives of Medical Science-Civilization Diseases. 2017;2(1):62-9.
• 32. Chakraborty P, Ghosh S, Goswami S, Kabir SN, Chakravarty B, Jana K. Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biological trace element research. 2013;152(1):9-15.
• 33. Janet Y. Uriu-Adams CLK. Copper, oxidative stress, and human health. Molecular Aspects of Medicine. 2008;26:268-98.
• 34. Kurdoglu Z OH, Tuluce Y, Koyuncu. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. Journal of Endocrinological Investigation. 2012;35(3):317-21.
• 35. Mahjoub S, & Masrour-Roudsari, J. Role of oxidative stress in pathogenesis of metabolic syndrome. . Caspian journal of internal medicine. 2012;3.1 386.
• 36. Celik C, Bastu E, Abali R, Alpsoy S, Guzel EC, Aydemir B, et al. The relationship between copper, homocysteine and early vascular disease in lean women with polycystic ovary syndrome. Gynecological Endocrinology. 2013;29(5):488-91.
• 37. Kanafchian M, Esmaeilzadeh S, Mahjoub S, Rahsepar M, Ghasemi M. Status of serum copper, magnesium, and total antioxidant capacity in patients with polycystic ovary syndrome. Biological Trace Element Research. 2020;193(1):111-7.
• 38. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertility sterility. 2003;80(1):123-7.
• 39. Kurdoglu Z, Kurdoglu M, Demir H, Sahin H. Serum trace elements and heavy metals in polycystic ovary syndrome. Human experimental toxicology. 2012;31(5):452-6.